Duotrav: Clinical Trials

13 trials of Duotrav, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 terminated, 1 withdrawn. 13 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 413Completed 10, Terminated 2, Withdrawn 1

Follow Duotrav: new trials by email Literature Review of Duotrav trials Research Report on Duotrav

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution - Open-angle Glaucoma, Ocular Hypertension
Phase 4TerminatedAlcon Research1732016-06-242019-05-29
Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma
Brimonidine Tartrate, Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops, Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension - Glaucoma, Open-Angle
Phase 4CompletedAfyon Kocatepe University Hospital962014-01-012019-05-29
Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure
Beta-blocker monotherapy, Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution - Open Angle Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research1572013-12-012016-08-08
Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia
Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav) - Glaucoma, Ocular Hypertension
Phase 4WithdrawnAlcon Research2013-02-012013-02-07
Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy
Travoprost/Timolol Maleate BAK-Free Fixed Combination - Glaucoma
Phase 4TerminatedAlcon Research372012-06-012014-12-03
Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction
travoprost ophthalmic solution 0.004%, travoprost 0.004% / timolol 0.5% combination ophthalmic solution, Bimatoprost ophthalmic solution 0.01% - Glaucoma, Open-Angle, Ocular Hypertension
Phase 4CompletedAllergan1352011-12-012014-08-15
Efficacy of Changing to DUOTRAV® From Prior Therapy
Travoprost 0.004%+Timolol 0.5% ophthalmic solution - Open-Angle Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research602011-08-012014-02-10
Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol
Travoprost 0.004%/timolol maleate 0.5% fixed combination - Glaucoma
Phase 4CompletedAlcon Research502011-02-012013-07-08
Safety and Efficacy of Changing to DuoTrav From Prior Therapy
Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®) - Glaucoma
Phase 4CompletedAlcon Research1052010-10-012016-11-21
DuoTrav® Eye Drops As Replacement Therapy Program
DuoTrav - Open-angle Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research1282009-02-012012-09-20
A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma
DuoTrav (travoprost-timolol ophthalmic drops), Xalacom (latanoprost-timolol ophthalmic drops) - Open-Angle Glaucoma, Ocular Hypertension
Phase 4CompletedOphthalmic Consultants Centres, Canada542009-01-012015-04-21
Adherence Assessment With Travalert Dosing Aid
Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav), Travoprost 0.004% eye drops, Timolol 0.05% eye drops - Open-angle Glaucoma, Ocular Hypertension
Phase 4CompletedAlcon Research1022007-10-012012-07-12
Success of Transitioning Uncontrolled Glaucoma Patients From Prior Mono or Adjunctive Therapy to DuoTrav
Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav) - Glaucoma
Phase 4CompletedAlcon Research5222007-08-012016-11-18

Conditions studied

Glaucoma, Open-Angle (10)  ·  Ocular Hypertension (10)  ·  Glaucoma (7)  ·  Patient Compliance (1)

Sponsors

Alcon Research (10)  ·  Afyon Kocatepe University Hospital (1)  ·  Allergan (1)  ·  Ophthalmic Consultants Centres, Canada (1)

Countries

Canada (2)  ·  Germany (2)  ·  United States (2)  ·  Brazil (1)  ·  China (1)  ·  Spain (1)

Top investigators

Abayomi Ogundele, PharmD (3)  ·  David B Yan, MD (1)  ·  Dr Francisco M. Honrubia (1)  ·  Mark C Jasek (1)  ·  Navroop Gill, OD (1)  ·  Severine Durier, Pharm.D (1)

Results publications

PMID 11589866, PMID 14736774, PMID 14996520, PMID 17415690, PMID 18826749, PMID 20505839, PMID 21773673, PMID 28239491, PMID 9098273

NIH funding

2016 (1)